Castle Biosciences (CSTL) announced new data demonstrating that its TissueCypher Barrett’s Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The research will be presented in three posters at the American College of Gastroenterology, ACG, 2025 Annual Scientific Meeting, taking place Oct. 27-29, 2025, in Phoenix, Arizona, including one selected for a Presidential Poster Award.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL: